Showing 1471-1480 of 1690 results for "".
- New PrecivityAD2 Blood Test as Accurate as CSF Biomarker and Amyloid PET Testinghttps://practicalneurology.com/news/p-tau-blood-tests-potentially-provide-greater-accuracy-and-earlier-diagnosis-for-alzheimer-disease/2470539/Two studies presented at the 2024 meeting of the Alzheimer’s Association International Conference (AAIC) suggest that high-performance blood tests are accurate and effective at assessing f
- Buntanetap Treatment for Parkinson Disease Linked to Improvements in Motor, Non-Motor, and Cognitive Functionshttps://practicalneurology.com/news/buntanetap-treatment-for-parkinson-disease-linked-to-improvements-in-motor-non-motor-and-cognitive-functions/2470527/Treatment with buntanetap (Annovis Bio, Malvern, PA), an oral molecule with potential therapeutic applications in neurodegenerative conditions such as Parkinson disease (PD) and Alzheimer disease (AD), was associated with improvements in motor and non-motor activities and cognitive functions in p
- Fintepla Reduced Seizures in Those with Developmental and Epileptic Encephalopathieshttps://practicalneurology.com/news/fintepla-reduced-seizures-in-those-with-developmental-and-epileptic-encephalopathies/2470519/Results of a meta-analysis published in Epilepsia demonstrated that Fintepla (fenfluramine; UCB, Atlanta, GA) treatment was associated with a reduction in the frequency of generalized tonic-clonic seizures (GTCS) and tonic-clonic seizures (TCS) in individuals with developmental and epile
- Improvements in Cognition, Alzheimer Disease Biomarkers Linked to Novel Small Molecule Drughttps://practicalneurology.com/news/improvements-in-cognition-alzheimer-disease-biomarkers-linked-to-treatment-with-buntanetap/2470512/Treatment with buntanetap (Annovis Bio, Malvern, PA), an oral molecule with potential therapeutic applications in neurodegenerative conditions such as Parkinson disease (PD) and Alzheimer disease (AD), was associated with significant improvements in cognition and biomarker measures in people with
- Eplontersen Improves Disease State and QoL in People with Hereditary ATTRv-PNhttps://practicalneurology.com/news/eplontersen-improves-disease-state-and-qol-in-people-with-hereditary-attrv-pn/2470305/In the phase 3 clinical trial NEURO-TTRansform (NCT04136184), treatment with eplontersen (AstraZeneca; Cambridge, UK; Ionis Pharmaceuticals, Carslbad, CA), an investigational ligand-conjugated antisense (LICA) medication that inhibits production of the transthyretin (TTR) protein, was associated
- Potential New Biomarker for CNS Demyelination Identifiedhttps://practicalneurology.com/news/potential-new-biomarker-for-cns-demyelination-identified/2470267/Results from a study recently published in JAMA Neurology identified myelin oligodendrocyte glycoprotein (MOG)-associated immunoglobulin A (IgA) in a small number of patients who were double negative for serum aquapo
- At Home Testing of Neurocognitive Function in People with Alzheimer Disease Shows Potential According to Study from Cumulus Neurosciencehttps://practicalneurology.com/news/at-home-testing-of-neurocognitive-function-in-people-with-alzheimer-disease-shows-potential-according-to-study-from-cumulus-neuroscience/2470255/A presentation at the 2023 meeting of the Alzheimer’s Association International Conference (AAIC) demonstrated the potential for at-home sampling of clinical data for patients with early stages of Alzheimer Disease (A
- Full Results from TRAILBLAZER-ALZ 2 Demonstrate Donanemab Effective at Slowing Cognitive and Functional Decline in Early Alzheimer Diseasehttps://practicalneurology.com/news/new-results-from-trailblazer-alz-2-demonstrate-donanemab-effective-at-slowing-cognitive-and-functional-decline-in-early-alzheimer-disease/2470243/The full results of the phase 3 TRAILBLAZER-ALZ 2 (NCT04437511) study were presented at the 2023 meeting of the Alzheimer’s Association International Conference (AAIC), showing that treatment with donanemab (Eli Lilly
- First US County-Level Alzheimer Dementia Assessment Documents Region-Specific Disease Prevalencehttps://practicalneurology.com/news/first-us-county-level-alzheimer-dementia-assessment-documents-region-specific-disease-prevalence/2470240/The first ever county-level Alzheimer dementia assessment in the United States estimated the region-specific burden of Alzheimer disease (AD). These results were presented at the 2023 Alzheimer’s Association Internati
- CRISPR/dCAS9 Shows Promise in Editing APOE ε4 to Treat Late Onset Alzheimer Diseasehttps://practicalneurology.com/news/crisprdcas9-shows-promise-in-editing-apoe-e4-to-treat-late-onset-alzheimer-disease/2470239/Results presented at the 2023 meeting of the Alzheimer’s Association International Conference (AAIC) demonstrate the potential of a novel CRISPR/dCas9-editing strategy to treat late onset Alzheimer disease (LOAD) by t